Free Trial

IQVIA (IQV) Stock Forecast & Price Target

IQVIA logo
$182.44 -3.42 (-1.84%)
Closing price 08/1/2025 03:59 PM Eastern
Extended Trading
$186.25 +3.81 (+2.09%)
As of 08/1/2025 07:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IQVIA - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
6
Buy
17

Based on 23 Wall Street analysts who have issued ratings for IQVIA in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 6 have given a hold rating, and 17 have given a buy rating for IQV.

Consensus Price Target

$228.62
25.31% Upside
According to the 23 analysts' twelve-month price targets for IQVIA, the average price target is $228.62. The highest price target for IQV is $276.00, while the lowest price target for IQV is $160.00. The average price target represents a forecasted upside of 25.31% from the current price of $182.44.
Get the Latest News and Ratings for IQV and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IQVIA and its competitors.

Sign Up

IQV Analyst Ratings Over Time

TypeCurrent Forecast
8/3/24 to 8/3/25
1 Month Ago
7/4/24 to 7/4/25
3 Months Ago
5/5/24 to 5/5/25
1 Year Ago
8/4/23 to 8/3/24
Strong Buy
0 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
17 Buy rating(s)
16 Buy rating(s)
16 Buy rating(s)
12 Buy rating(s)
Hold
6 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$228.62$226.32$237.62$262.40
Forecasted Upside25.31% Upside37.80% Upside56.02% Upside8.53% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

IQV Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IQV Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IQVIA Stock vs. The Competition

TypeIQVIAMedical CompaniesS&P 500
Consensus Rating Score
2.74
2.81
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside25.31% Upside10,407.36% Upside14.55% Upside
News Sentiment Rating
Positive News

See Recent IQV News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/25/2025Mizuho
3 of 5 stars
Ann Hynes
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$190.00 ➝ $225.00+13.90%
7/23/2025Cowen
1 of 5 stars
 Reiterated RatingBuy ➝ Buy
7/23/2025UBS Group
3 of 5 stars
Dan Leonard
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$185.00 ➝ $225.00+15.70%
7/23/2025William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
7/23/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jailendra Singh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$209.00 ➝ $235.00+22.12%
7/23/2025Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Luke Sergott
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$165.00 ➝ $185.00-1.54%
7/23/2025Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Eric Coldwell
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$159.00 ➝ $196.00+4.32%
7/9/2025Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Elizabeth Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOutperform ➝ Outperform$170.00 ➝ $180.00+9.30%
5/23/2025Redburn Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Jamie Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Target$188.00+37.26%
5/22/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral
5/19/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Anne Samuel
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$232.00 ➝ $177.00+25.40%
4/25/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Herholdt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
4/25/2025HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Rajesh Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$260.00 ➝ $160.00+6.17%
2/11/2025Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Tejas Savant
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$245.00 ➝ $250.00+24.05%
2/10/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Dodge
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$270.00 ➝ $270.00+31.00%
2/7/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Shlomo Rosenbaum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$273.00 ➝ $261.00+24.95%
2/3/2025BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Larsen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
12/20/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Garro
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$250.00+30.53%
12/13/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$255.00 ➝ $235.00+17.54%
11/19/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$260.00 ➝ $248.00+28.58%
11/1/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$270.00 ➝ $265.00+27.09%
11/1/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$270.00 ➝ $255.00+22.30%
11/1/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$280.00 ➝ $250.00+20.00%
10/14/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Clark
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$276.00+20.32%
7/31/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Toung
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/24/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold$266.00 ➝ $242.00+1.34%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Davis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/15/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:31 AM ET.


Should I Buy IQVIA Stock? IQV Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, July 31, 2025. Please send any questions or comments about these IQVIA pros and cons to contact@marketbeat.com.

IQVIA
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in IQVIA Holdings Inc.:

  • The stock has received multiple buy ratings from analysts, indicating strong confidence in its future performance.
  • Recent price targets from analysts suggest significant upside potential, with an average target around $228.62.
  • IQVIA Holdings Inc. has shown substantial growth in institutional ownership, with hedge funds owning over 89% of the stock, reflecting strong investor interest.
  • The current stock price is approximately $193.01, which may present a buying opportunity for investors looking for growth in the healthcare analytics sector.
  • Analysts project earnings per share of 10.84 for the current year, indicating solid profitability expectations.

IQVIA
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in IQVIA Holdings Inc. for these reasons:

  • The stock has experienced volatility, with recent trading showing fluctuations that could concern risk-averse investors.
  • Some analysts have downgraded their ratings, indicating potential caution regarding the stock's future performance.
  • The company has a relatively high debt-to-equity ratio of 2.45, which may raise concerns about financial stability and leverage.
  • Market conditions in the healthcare sector can be unpredictable, which may impact the company's growth and profitability.
  • Despite positive projections, there is always a risk that earnings may not meet expectations, which could negatively affect the stock price.

IQV Forecast - Frequently Asked Questions

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for IQVIA is $228.62, with a high forecast of $276.00 and a low forecast of $160.00.

23 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IQVIA in the last twelve months. There are currently 6 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IQV shares.

According to analysts, IQVIA's stock has a predicted upside of 25.31% based on their 12-month stock forecasts.

IQVIA has been rated by research analysts at Barclays, Citigroup, Cowen, Evercore ISI, JPMorgan Chase & Co., Mizuho, Redburn Partners, Robert W. Baird, Truist Financial, UBS Group, and William Blair in the past 90 days.

Analysts like IQVIA less than other "medical" companies. The consensus rating score for IQVIA is 2.74 while the average consensus rating score for "medical" companies is 2.81. Learn more on how IQV compares to other companies.


This page (NYSE:IQV) was last updated on 8/3/2025 by MarketBeat.com Staff
From Our Partners